{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:04:22Z","timestamp":1788494662734,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.neurol.2025.03.001","type":"journal-article","created":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T10:44:06Z","timestamp":1743590646000},"page":"535-543","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Trends in the real-world management of patients with active relapsing-remitting multiple sclerosis treated with natalizumab (TYSABRI\u00ae) in France: An analysis of the PMSI database over five years (2019\u20132023)"],"prefix":"10.1016","volume":"181","author":[{"given":"E.","family":"Le Page","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Emery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Fravalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Fagnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Clement","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2025.03.001_bib0150","first-page":"1","article-title":"Natalizumab extended-interval dosing in multiple sclerosis to mitigate progressive multifocal leukoencephalopathy risk: initial study evidence and real-world experience","volume":"14","author":"Perncezky","year":"2022","journal-title":"J Cent Nerv Syst Dis"},{"issue":"15","key":"10.1016\/j.neurol.2025.03.001_bib0155","first-page":"e1452","article-title":"Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing","volume":"93","author":"Zhovtis Ryerson","year":"2019","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.neurol.2025.03.001_bib0160","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/S1474-4422(22)00143-0","article-title":"Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial","volume":"21","author":"Foley","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2025.03.001_bib0165","unstructured":"European Union (EU). Risk Management Plan (RMP) for TYSABRI\u00ae (NATALIZUMAB) RMP version 22 February 2024, page 34. Available at https:\/\/www.ema.europa.eu\/en\/documents\/rmp\/tysabri-epar-risk-management-plan_en.pdf [accessed 10 December 2024]."},{"key":"10.1016\/j.neurol.2025.03.001_bib0170","unstructured":"Vukusic S, Ciron J, Carra-Dalliere C, Maillart E, Michel L, Leray E, et al. Grossesse dans la scl\u00e9rose en plaques et les maladies du spectre de la NMO recommandations de la SFSEP (April 14, 2022). Available at: https:\/\/sfsep.org\/wp-content\/uploads\/2022\/04\/SFSEP_Presentation-Recos_Gossesse-20220414.pdf [accessed 10 December 2024]."},{"key":"10.1016\/j.neurol.2025.03.001_bib0180","unstructured":"ANSM decision. Available at: https:\/\/ansm.sante.fr\/actualites\/decision-du-29-12-2023-portant-modification-de-la-liste-de-reference-des-groupes-biologiques-similaires-mentionnee-a-larticle-r-5121-9-1-du-code-de-la-sante-publique [accessed 10 December 2024]."},{"issue":"7","key":"10.1016\/j.neurol.2025.03.001_bib0185","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.healthpol.2021.04.012","article-title":"Hospital payment schemes and high-priced drugs: evidence from the French add-on list","volume":"125","author":"Rachet-Jacquet","year":"2021","journal-title":"Health Policy"},{"issue":"1","key":"10.1016\/j.neurol.2025.03.001_bib0190","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1186\/s12913-019-4295-7","article-title":"The experience of patients and family caregivers during hospital-at-home in France","volume":"19","author":"Rossinot","year":"2019","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.neurol.2025.03.001_bib0195","series-title":"Circulaire no\u00a0DHOS\/O3\/2006\/506 du 1er d\u00e9cembre 2006 relative \u00e0 l\u2019hospitalisation \u00e0 domicile (HAD)","year":"2006"},{"key":"10.1016\/j.neurol.2025.03.001_bib0200","unstructured":"https:\/\/had35.fr\/2020\/11\/25\/tysabri\/#:\u223c:text=Dans%20le%20contexte%20sanitaire%20li%C3%A9,de%20l'hospitalisation%20%C3%A0%20domicile [accessed 10 December 2024]."},{"issue":"2","key":"10.1016\/j.neurol.2025.03.001_bib0205","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/13524585231223395","article-title":"Use of multiple sclerosis disease-modifying therapies during pregnancy in France: nationwide study between 2010 and 2021","volume":"30","author":"Swital","year":"2024","journal-title":"Mult Scler"},{"issue":"5","key":"10.1016\/j.neurol.2025.03.001_bib0210","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.neurol.2023.12.007","article-title":"Prevalence of multiple sclerosis in France in 2021: data from the French health insurance database","volume":"180","author":"Pierret","year":"2024","journal-title":"Rev Neurol (Paris)"},{"issue":"15","key":"10.1016\/j.neurol.2025.03.001_bib0215","doi-asserted-by":"crossref","first-page":"e1452","DOI":"10.1212\/WNL.0000000000008243","article-title":"Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing","volume":"93","author":"Ryerson","year":"2019","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.neurol.2025.03.001_bib0220","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1177\/1352458518815602","article-title":"Observatoire fran\u00e7ais de la scl\u00e9rose en plaques (OFSEP): a unique multimodal nationwide MS registry in France","volume":"26","author":"Vukusic","year":"2020","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurol.2025.03.001_bib0225","unstructured":"OFSEP cohort. https:\/\/www.ofsep.org\/fr\/la-cohorte-ofsep\/descriptif-de-la-cohorte [accessed 10 December 2024]."},{"issue":"1","key":"10.1016\/j.neurol.2025.03.001_bib0230","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12955-022-02046-1","article-title":"Understanding lifestyle self-management regimens that improve the life quality of people living with multiple sclerosis: a systematic review and meta-analysis","volume":"20","author":"Wills","year":"2022","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.neurol.2025.03.001_bib0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/17562864241241382","article-title":"Real-world evidence and patient preference for subcutaneous versus intravenous natalizumab in the treatment of relapsing-remitting multiple sclerosis \u2013 initial results from the observational SISTER study","volume":"17","author":"Gold","year":"2024","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.neurol.2025.03.001_bib0240","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2147\/PPA.S303279","article-title":"Patient preferences for subcutaneous versus intravenous administration of treatment for chronic immune system disorders: a systematic review","volume":"15","author":"Overton","year":"2021","journal-title":"Patient Prefer Adherence"},{"issue":"8","key":"10.1016\/j.neurol.2025.03.001_bib0245","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1002\/acn3.51410","article-title":"Home infusions of natalizumab for people with multiple sclerosis: a pilot randomised crossover trial","volume":"8","author":"Schultz","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.neurol.2025.03.001_bib0250","doi-asserted-by":"crossref","first-page":"104657","DOI":"10.1016\/j.msard.2023.104657","article-title":"Switching from natalizumab administration at the day hospital to administration at home. A 1 year prospective study of patient experience and quality of life in 30 consecutive patients with multiple sclerosis (TYSAD-35)","volume":"73","author":"Lamy","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurol.2025.03.001_bib0255","unstructured":"European Medicines Agency (EMA). https:\/\/www.ema.europa.eu\/en\/documents\/procedural-steps-after\/tysabri-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf Page 5, application number II\/0136 as of 25-01-2024 [accessed 10 December 2024]."},{"key":"10.1016\/j.neurol.2025.03.001_bib0260","doi-asserted-by":"crossref","first-page":"104958","DOI":"10.1016\/j.msard.2023.104958","article-title":"Exploring the socio-ecological factors impacting lifestyle management of multiple sclerosis: a scoping review","volume":"79","author":"Manche","year":"2023","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"10.1016\/j.neurol.2025.03.001_bib0265","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s40120-023-00440-5","article-title":"Real-world effectiveness of natalizumab extended interval dosing in a French cohort","volume":"12","author":"Pelle","year":"2023","journal-title":"Neurol Ther"},{"issue":"10","key":"10.1016\/j.neurol.2025.03.001_bib0270","first-page":"e832","article-title":"Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: maternal risks","volume":"90","author":"Portaccio","year":"2018","journal-title":"Neurology [Internet]"},{"issue":"1","key":"10.1016\/j.neurol.2025.03.001_bib0275","doi-asserted-by":"crossref","first-page":"e424","DOI":"10.1212\/NXI.0000000000000424","article-title":"Disease activity following pregnancy-related discontinuation of natalizumab in MS","volume":"5","author":"Kleerekooper","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"24","key":"10.1016\/j.neurol.2025.03.001_bib0280","doi-asserted-by":"crossref","first-page":"e2989","DOI":"10.1212\/WNL.0000000000012084","article-title":"Natalizumab, fingolimod and dimethyl fumarate use and pregnancy-related relapse and disability in women with multiple sclerosis","volume":"96","author":"Yeh","year":"2021","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.neurol.2025.03.001_bib0285","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1177\/1352458520912637","article-title":"Maintenance of natalizumab during the first trimester of pregnancy in active multiple sclerosis","volume":"27","author":"Demortiere","year":"2021","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurol.2025.03.001_bib0290","doi-asserted-by":"crossref","first-page":"104122","DOI":"10.1016\/j.msard.2022.104122","article-title":"Disease modifying therapies and disease activity during pregnancy and postpartum in a contemporary cohort of relapsing multiple sclerosis patients","volume":"68","author":"Lescot","year":"2022","journal-title":"Mult Scler Relat Disord"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378725004679?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378725004679?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T02:06:24Z","timestamp":1750212384000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378725004679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0035378725004679"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2025.03.001","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trends in the real-world management of patients with active relapsing-remitting multiple sclerosis treated with natalizumab (TYSABRI\u00ae) in France: An analysis of the PMSI database over five years (2019\u20132023)","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2025.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}